Drug Profile

Research programme: mental disorder therapeutics - Cybin

Alternative Names: Deuterated DMT IV series - Cybin; Deuterated DMT series - Cybin

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Small Pharma
Developer Cybin
Class Dimethylamines; Neuropsychotherapeutics; Organic deuterium compounds; Small molecules; Tryptamines
Mechanism of Action Serotonin receptor modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Apr 2025 No recent reports of development identified for preclinical development in Mental-disorders in United Kingdom (IV)
07 Feb 2024 Cybin has patent protection for DMT and dDMT compounds in Japan
25 Oct 2023 Cybin has patent protection for Deuterated compounds in USA (US1 177 306 2B2)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com